Skip to main content

Guido Ferrari, MD

Professor in Surgery
Research Professor in Molecular Genetics and Microbiology
Office: 915 S. Lasalle Street, Sorf Building Room 208, Durham, NC 27710
Campus Mail: DUMC Box 2926 Med Ctr, Durham, NC 27710

The activities of the Ferrari Laboratory are based on both independent basic research and immune monitoring studies. The research revolves around three main areas of interest: class I-mediated cytotoxic CD8+ T cell responses, antibody-dependent cellular cytotoxicity (ADCC), gene expression in NK and T cellular subsets upon infection with HIV-1. With continuous funding over the last 11 years from the NIH and Bill & Melinda Gates Foundation along with many other productive collaborations within and outside of Duke, the Ferrari Lab has expanded its focus of research to include the ontogeny of HIV-1 specific immune responses that work by eliminating HIV-1 infected cells and how these can be induced by AIDS vaccine candidates.

Education and Training

  • M.D., University of Genoa (Italy), 1985

Selected Grants

Publications

Mitchell, Julie L., Justin Pollara, Kenneth Dietze, R Whitney Edwards, Junsuke Nohara, Kombo F. N’guessan, Michelle Zemil, et al. “Anti-HIV antibody development up to one year after antiretroviral therapy initiation in acute HIV infection.” J Clin Invest, November 11, 2021. https://doi.org/10.1172/JCI150937.

Full Text

Saunders, Kevin O., Norbert Pardi, Robert Parks, Sampa Santra, Zekun Mu, Laura Sutherland, Richard Scearce, et al. “Author Correction: Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates.” Npj Vaccines 6, no. 1 (November 6, 2021): 136. https://doi.org/10.1038/s41541-021-00397-2.

Full Text

Mielke, Dieter, Gama Bandawe, Jie Zheng, Jennifer Jones, Melissa-Rose Abrahams, Valerie Bekker, Christina Ochsenbauer, et al. “ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection.” Plos Pathog 17, no. 11 (November 2021): e1010046. https://doi.org/10.1371/journal.ppat.1010046.

Full Text

Cheng, Hao D., Karen G. Dowell, Chris Bailey-Kellogg, Brittany A. Goods, J Christopher Love, Guido Ferrari, Galit Alter, et al. “Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features.” Retrovirology 18, no. 1 (October 30, 2021): 35. https://doi.org/10.1186/s12977-021-00579-9.

Full Text

Sherburn, Rebekah, William D. Tolbert, Suneetha Gottumukkala, Andrew P. Hederman, Guillaume Beaudoin-Bussières, Sherry Stanfield-Oakley, Marina Tuyishime, et al. “Incorporating the Cluster A and V1V2 Targets into a Minimal Structural Unit of the HIV-1 Envelope to Elicit a Cross-Clade Response with Potent Fc-Effector Functions.” Vaccines 9, no. 9 (August 31, 2021). https://doi.org/10.3390/vaccines9090975.

Full Text

Pino, Maria, Talha Abid, Susan Pereira Ribeiro, Venkata Viswanadh Edara, Katharine Floyd, Justin C. Smith, Muhammad Bilal Latif, et al. “A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates.” Sci Immunol 6, no. 61 (July 15, 2021). https://doi.org/10.1126/sciimmunol.abh3634.

Full Text

Chua, Joel V., Charles Davis, Jennifer S. Husson, Amy Nelson, Ilia Prado, Robin Flinko, Ka Wing J. Lam, et al. “Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial.” Vaccine 39, no. 29 (June 29, 2021): 3879–91. https://doi.org/10.1016/j.vaccine.2021.05.090.

Full Text

Saunders, Kevin O., Norbert Pardi, Robert Parks, Sampa Santra, Zekun Mu, Laura Sutherland, Richard Scearce, et al. “Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates.” Npj Vaccines 6, no. 1 (April 9, 2021): 50. https://doi.org/10.1038/s41541-021-00307-6.

Full Text

Tolbert, William D., Verna Van, Rebekah Sherburn, Marina Tuyishime, Fang Yan, Dung N. Nguyen, Sherry Stanfield-Oakley, et al. “Erratum for Tolbert et al., "Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial".” Mbio 12, no. 2 (April 6, 2021). https://doi.org/10.1128/mBio.00474-21.

Full Text

Andersen-Nissen, Erica, Andrew Fiore-Gartland, Lamar Ballweber Fleming, Lindsay N. Carpp, Anneta F. Naidoo, Michael S. Harper, Valentin Voillet, et al. “Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk.” Plos Pathog 17, no. 3 (March 2021): e1009363. https://doi.org/10.1371/journal.ppat.1009363.

Full Text

Pages